AVRO:NSD-AVROBIO, Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 7.58

Change

+0.22 (+2.99)%

Market Cap

USD 0.31B

Volume

0.12M

Avg Analyst Target

USD 14.00 (+84.70%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

AVROBIO, Inc., a clinical-stage gene therapy company, develops ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose worldwide. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene that is defective in the target disease. The company's lead product candidate is AVR-RD-01, a gene therapy which is in ongoing company-sponsored Phase 2 clinical trial and investigator-sponsored Phase 1 clinical trial for the treatment of Fabry disease. It is also developing AVR-RD-02, which is in Phase 1/2 clinical trial for the treatment of type 1 Gaucher disease; AVR-RD-03, which is in preclinical development to treat Pompe disease; AVR-RD-04 that is in investigator-sponsored Phase 1/2 clinical trial to treat cystinosis; AVR-RD-05 for the treatment of Hunter syndrome; and AVR-RD-06 that is in preclinical stage to treat Gaucher disease type 3. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Company Website : http://www.avrobio.com

Address : Building 300, Cambridge, MA, United States, 02139

Employees : 121

Fiscal Year End : December

Currency: USD

Country : USA

Technical Indicators

Beta : 1.36

52 Week High : 20.07

Short Ratio : 8.06

52 Week Low : 7.16

Shorted Shares : 3,592,531

200 Day Moving Average : 10.98

Shorted Shares Previous Month : 3,540,998

50 Day Moving Average : 8.60

Shares Held By Insiders : 3.07%

Short Percentage : 9.00%

Shares Held by Institutions : 90.83%

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-08-02 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna, Inc

-6.99 (-1.98%)

 USD141.98B 237.00 190.09
BNTX BioNTech SE

+11.86 (+3.61%)

 USD79.30B 59.35 50.07
REGN Regeneron Pharmaceuticals, Inc

+2.52 (+0.44%)

 USD61.22B 16.36 12.83
VRTX Vertex Pharmaceuticals Incorpo..

-3.26 (-1.62%)

 USD52.23B 26.58 13.36
ALXN Alexion Pharmaceuticals, Inc

N/A

 USD40.34B 59.23 42.56
GMAB Genmab A/S

+0.12 (+0.27%)

 USD29.62B 33.28 3.77
BGNE BeiGene, Ltd

+10.83 (+3.42%)

 USD29.25B N/A N/A
SGEN Seagen Inc

+0.85 (+0.55%)

 USD27.91B 47.87 38.34
RPRX Royalty Pharma plc

-0.99 (-2.59%)

 USD23.19B 31.49 13.92
ALNY Alnylam Pharmaceuticals, Inc

-0.98 (-0.55%)

 USD21.03B N/A N/A

ETFs Containing AVRO

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -45.62% 13% F 6% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -45.62% 13% F 6% F
Trailing 12 Months  
Capital Gain -56.34% 12% F 4% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -56.34% 12% F 4% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -12.15% 18% F 8% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -12.15% 18% F 7% F
Risk Return Profile  
Volatility (Standard Deviation) 29.40% 87% B+ 61% D-
Risk Adjusted Return -41.32% 14% F 6% F
Market Capitalization 0.31B 49% F 41% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 1.32 88% B+ 76% C
Price / Cash Flow Ratio -3.11 26% F 60% D-
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -49.30% 56% F 29% F
Return on Invested Capital -54.60% 44% F 15% F
Return on Assets -29.22% 38% F 11% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 8.06 19% F 11% F
Short Percent 10.95% 26% F 17% F
Beta 1.36 50% F 36% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.